DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.

Dr. Loren  Clarke M.D.

Chief Medical Officer

Mr. Kevin  Sun M.B.A.

Chief Financial Officer, Treasurer & Secretary

Mr. Mark  Aguillard

Chief Commercial Officer

Mr. Bret  Christensen

President, Chief Executive Officer & Director

Dr. Steven  Stone Ph.D.

Senior Vice President of Research & Development

Mr. William W. Zondler

Chief Information Officer

Ms. Jennifer  Eilemberg

Chief Compliance Officer

Mr. Steve E. Kunszabo

Senior Director of Investor Relations

Dr. Burkhard  Jansen M.D.

Chief Medical Affairs Officer

Mr. Ray  Akhavan Esq., J.D.

General Counsel

Diagnostik und Forschung

DermTech, Inc.

DermTech, Inc. Management-Struktur

Informationen zum Management